External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Equity Bottom-Up

Jacobio Pharmaceuticals / Equity Bottom-Up

<ul><li>Jacobio’s core investment case continues to strengthen following the latest clinical update for JAB-23E73, its differentiated pan-KRAS small-molecule inhibitor.</li><li>Updated data further validate the asset’s compelling antitumor activity and favorable tolerability, which we believe distinguishes it from competing panRAS approaches.</li><li>Backed by first-mover positioning, a cleaner intellectual property pathway, and manufacturing advantage as a small molecule, we view JAB-23E73 as a potential blockbuster asset. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Jacobio’s core investment case continues to strengthen following the latest clinical update for JAB-23E73, its differentiated pan-KRAS small-molecule inhibitor.Updated data further validate the asset’s compelling antitumor activity and favorable tolerability, which we believe distinguishes it from competing panRAS approaches.Backed by first-mover positioning, a cleaner intellectual property pathway, and manufacturing advantage as a small molecule, we view JAB-23E73 as a potential blockbuster asset. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Jacobio (1167 HK) - Differentiated Safety and Promising Efficacy of JAB-23E73 Further Validated

<ul><li>Jacobio’s JAB-23E73 (pan-KRAS) has demonstrated a highly differentiated safety profile and promising early efficacy.</li><li>We believe that due to its superior safety compared to competitors like RVMD’s RMC-6236 and encouraging early efficacy signals, JAB-23E73 holds significant blockbuster potential.</li><li>We estimate the global risk-adjusted peak sales of JAB-23E73 to reach US$2.1bn. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Jacobio’s JAB-23E73 (pan-KRAS) has demonstrated a highly differentiated safety profile and promising early efficacy.We believe that due to its superior safety compared to competitors like RVMD’s RMC-6236 and encouraging early efficacy signals, JAB-23E73 holds significant blockbuster potential.We estimate the global risk-adjusted peak sales of JAB-23E73 to reach US$2.1bn. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Jacobio (1167 HK) - Early Pan-KRAS Clinical Data Unveils Potential First-In-Class Blockbuster

Thematic (Sector/Industry)

<ul><li>The Chinese biotech / biopharma sector is entering a pivotal phase in 2026, driven by accelerating global BD partnerships, pivotal clinical data readouts, and key overseas regulatory milestones.</li><li>As the industry transitions into a "new pillar industry" under supportive government policies, we believe the market is underestimating the pipeline value of leading Chinese biotech companies.</li><li>In particular, the oncology pipeline comprises several high-conviction readouts this year, including Akeso/Summit's ivonescimab trials (HARMONi-6 and HARMONi3), Innovent's IBI363 data in first-line NSCLC and colorectal cancer, and DualityBio's ADC-plus-BNT327 combinations, which have the potential to reshape the oncology competitive landscape. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

The Chinese biotech / biopharma sector is entering a pivotal phase in 2026, driven by accelerating global BD partnerships, pivotal clinical data readouts, and key overseas regulatory milestones.As the industry transitions into a "new pillar industry" under supportive government policies, we believe the market is underestimating the pipeline value of leading Chinese biotech companies.In particular, the oncology pipeline comprises several high-conviction readouts this year, including Akeso/Summit's ivonescimab trials (HARMONi-6 and HARMONi3), Innovent's IBI363 data in first-line NSCLC and colorectal cancer, and DualityBio's ADC-plus-BNT327 combinations, which have the potential to reshape the oncology competitive landscape. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

A Catalyst-Rich 2026: Valuation Re-Rating Opportunities for Chinese Biotechs / Biopharmas

China

Jacobio Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to the in-house discovery and development of innovative oncology therapies, focusing on "undruggable" targets in key oncogenic pathways. They leverage their Induced Allosteric Molecule Discovery Platform and iADC Platform to develop novel drugs, including clinical-stage candidates like Glecirasib (KRAS G12C inhibitor) and Sitneprotafib (SHP2 inhibitor) for various solid tumors. The company was founded in 2015 and is headquartered in Beijing, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Jacobio Pharmaceuticals (1167 HK)

Jacobio (1167 HK) - Differentiated Safety and Promising Efficacy of JAB-23E73 Further Validated

Jacobio’s core investment case continues to strengthen following the latest clinical update for JAB-23E73, its differentiated pan-KRAS small...

CMB International

Jacobio (1167 HK) - Early Pan-KRAS Clinical Data Unveils Potential First-In-Class Blockbuster

We believe that due to its superior safety compared to competitors like RVMD’s RMC-6236 and encouraging early efficacy signals, JAB-23E73 holds...

CMB International

A Catalyst-Rich 2026: Valuation Re-Rating Opportunities for Chinese Biotechs / Biopharmas

The Chinese biotech / biopharma sector is entering a pivotal phase in 2026, driven by accelerating global BD partnerships, pivotal clinical data...

CMB International

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)